Chia‐Chi Lin
About
Chia‐Chi Lin is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Chia‐Chi Lin has authored 25 papers receiving a total of 637 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Chia‐Chi Lin's work include Thyroid Cancer Diagnosis and Treatment (8 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Chia‐Chi Lin is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (8 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Chia‐Chi Lin collaborates with scholars based in Taiwan, United States and Japan. Chia‐Chi Lin's co-authors include Rita Chiari, Enriqueta Felip, Todd M. Bauer, Antonello Abbattista, Alice T. Shaw, Holger Thurm, Jean‐François Martini, Benjamin Solomon, Shirish M. Gadgeel and Gregory J. Riely and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Chia‐Chi Lin
23 papers receiving 626 citations
Hit Papers
Peers
Chia‐Chi Lin
Hidenori Mizugaki Japan
Junzhou Wu China
Òscar Reig Spain
Hualei Gan China
Hielke J. Meulenbeld Netherlands
Irene De Santo Italy
Yoshimasa Kosaka Japan
Valeria Merz Italy
Alessandra Capodanno Italy
W. M. Linehan United States
Citations per year, relative to Chia‐Chi Lin Chia‐Chi Lin (= 1×)
peers
Hidenori Mizugaki
Countries citing papers authored by Chia‐Chi Lin
Since
Specialization
Citations
This map shows the geographic impact of Chia‐Chi Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chia‐Chi Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chia‐Chi Lin more than expected).
Fields of papers citing papers by Chia‐Chi Lin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Chia‐Chi Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chia‐Chi Lin. The network helps show where Chia‐Chi Lin may publish in the future.
Co-authorship network of co-authors of Chia‐Chi Lin
This figure shows the co-authorship network connecting the top 25 collaborators of Chia‐Chi Lin. A scholar is included among the top collaborators of Chia‐Chi Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chia‐Chi Lin. Chia‐Chi Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Capdevila, Jaume, Jolanta Krajewska, Jorge Hernando, et al.. (2023). Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 34(3). 347–359.
2.
Brose, Marcia S., Johannes W. A. Smit, Chia‐Chi Lin, et al.. (2022). Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). Thyroid. 32(9). 1059–1068.
3.
Villalona‐Calero, Miguel A., Amita Patnaik, Robert G. Maki, et al.. (2022). Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS3167–TPS3167.
4.
Capdevila, Jaume, Bruce Robinson, Steven I. Sherman, et al.. (2022). Cabozantinib versus placebo in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes in prespecified subgroups based on histology subtypes.. Journal of Clinical Oncology. 40(16_suppl). 6081–6081.
5.
Lee, Keun Wook, Young‐Hyuck Im, Keun Seok Lee, et al.. (2021). Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.. Journal of Clinical Oncology. 39(15_suppl). TPS2656–TPS2656.
6.
Shih, Shyang‐Rong, Shu‐Lang Liao, Yi‐Hsuan Wei, et al.. (2019). Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy. Ocular Immunology and Inflammation. 29(1). 193–202.
7.
Ma, Weili, Chia‐Chi Lin, Feng‐Ming Hsu, et al.. (2019). Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. Clinical Lung Cancer. 20(6). e609–e618.
8.
Hussain, Syed A., Pablo Maroto, Miguel Ángel Climent, et al.. (2019). Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.. Journal of Clinical Oncology. 37(15_suppl). 5030–5030.
9.
Shaw, Alice T., Benjamin Solomon, Benjamin Besse, et al.. (2019). ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 37(16). 1370–1379.
10.
Brose, Marcia S., Fabián Pitoia, Johannes W. A. Smit, et al.. (2018). Second interim analysis of RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).. Journal of Clinical Oncology. 36(15_suppl). 6081–6081.
11.
Brose, Marcia S., Johannes W. A. Smit, Chia‐Chi Lin, et al.. (2017). Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocrine Related Cancer. 24(5). 237–242.
12.
Lu, Jinying, Wern‐Cherng Cheng, Kuan-Yuan Chen, et al.. (2017). Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancers. Journal of the Formosan Medical Association. 117(6). 488–496.
13.
Liao, Wei‐Yu, Chao‐Chi Ho, Kuan‐Yu Chen, et al.. (2017). Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. The Oncologist. 22(9). 1075–1083.
14.
Lin, Chia‐Chi, Kai‐Yuan Tzen, Yun‐Chun Wu, et al.. (2017). A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.. Journal of Clinical Oncology. 35(15_suppl). 4042–4042.
15.
Ritchlin, Christopher T., et al.. (2016). A Randomized, Double-blind, Active-and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Antirheumatic Drugs with Active Psoriatic Arthritis. Experimental Dermatology. 26(3). 1169–1169.
16.
Kang, Yoon‐Koo, Patricia LoRusso, Ravi Salgia, et al.. (2015). Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).. Journal of Clinical Oncology. 33(3_suppl). 167–167.
17.
Stadler, Walter M., David J. Vaughn, Guru Sonpavde, et al.. (2013). An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 120(7). 976–982.
18.
Lin, Chia‐Chi, Chih‐Hung Hsu, Jason Chia‐Hsien Cheng, et al.. (2013). Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology. 31(15_suppl). 4099–4099.
19.
Lin, Chia‐Chi, et al.. (2012). Abstract 3725: Combined cytotoxic effects of volasertib and cisplatin in urothelial carcinoma cells. Cancer Research. 72(8_Supplement). 3725–3725.
20.
Chen, Chien-Chih, et al.. (2006). Clinical evaluation of the eBsensor hand-held blood glucose monitoring system. Clinica Chimica Acta. 377(1-2). 170–173.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hidenori Mizugaki Breakdown of academic impact, for papers by Junzhou Wu Breakdown of academic impact, for papers by Òscar Reig Breakdown of academic impact, for papers by Hualei Gan Breakdown of academic impact, for papers by Hielke J. Meulenbeld Breakdown of academic impact, for papers by Irene De Santo Breakdown of academic impact, for papers by Yoshimasa Kosaka Breakdown of academic impact, for papers by Valeria Merz Breakdown of academic impact, for papers by Alessandra Capodanno Breakdown of academic impact, for papers by W. M. Linehan